Cited by 277Drug-Induced Hepatotoxicity and ProtectionMitochondrial Function and PathologyLiver physiology and pathology

Central role of mitochondria in drug-induced liver injury

Pessayre, Dominique, Fromenty, Bernard, Berson, Alain, Robin, Marie-Anne, Lettéron, Philippe, Moreau, Richard, Mansouri, Abdellah·2012·Drug Metabolism Reviews

Abstract

A frequent mechanism for drug-induced liver injury (DILI) is the formation of reactive metabolites that trigger hepatitis through direct toxicity or immune reactions. Both events cause mitochondrial membrane disruption. Genetic or acquired factors predispose to metabolite-mediated hepatitis by increasing the formation of the reactive metabolite, decreasing its detoxification, or by the presence of critical human leukocyte antigen molecule(s). In other instances, the parent drug itself triggers mitochondrial membrane disruption or inhibits mitochondrial function through different mechanisms. Drugs can sequester coenzyme A or can inhibit mitochondrial β-oxidation enzymes, the transfer of electrons along the respiratory chain, or adenosine triphosphate (ATP) synthase. Drugs can also destroy mitochondrial DNA, inhibit its replication, decrease mitochondrial transcripts, or hamper mitochondrial protein synthesis. Quite often, a single drug has many different effects on mitochondrial function. A severe impairment of oxidative phosphorylation decreases hepatic ATP, leading to cell dysfunction or necrosis; it can also secondarily inhibit ß-oxidation, thus causing steatosis, and can also inhibit pyruvate catabolism, leading to lactic acidosis. A severe impairment of β-oxidation can cause a fatty liver; further, decreased gluconeogenesis and increased utilization of glucose to compensate for the inability to oxidize fatty acids, together with the mitochondrial toxicity of accumulated free fatty acids and lipid peroxidation products, may impair energy production, possibly leading to coma and death. Susceptibility to parent drug-mediated mitochondrial dysfunction can be increased by factors impairing the removal of the toxic parent compound or by the presence of other medical condition(s) impairing mitochondrial function. New drug molecules should be screened for possible mitochondrial effects.

Integrity signals

Registry

Crossref · 10.3109/03602532.2011.604086

Cites

604 of 604 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A.
Affiliations
Inserm (FR)
Corresponding author
Pessayre, Dominique
Venue
Drug Metabolism Reviews
Published
2012-01-30
Volume
44
Issue
1
Pages
34-87
ISSN
  • 0360-2532 (ISSN-L)
  • 1097-9883
OpenAlex
W2076781542
Cited by
277
References
604
Citations by year
2026: 13 · 2025: 17 · 2024: 11 · 2023: 21 · 2022: 22 · 2021: 31 · 2020: 16 · 2019: 15 · 2018: 26 · 2017: 19 · 2016: 21 · 2015: 26 · 2014: 23 · 2013: 13 · 2012: 2
FWCI
1.75
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Metabolism Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
drug-induced liver injury, mitochondrial dysfunction, reactive drug metabolites, mitochondrial membrane disruption, oxidative phosphorylation, ATP synthase inhibition, mitochondrial DNA damage, lactic acidosis, hepatic steatosis, steatosis, lipid peroxidation, human leukocyte antigen, genetic susceptibility, drug safety testing
MeSH terms
DNA, Mitochondrial, Pharmaceutical Preparations, Fatty Liver, Humans, Immune System, Liver, Mitochondria, Liver, Oxidation-Reduction, Reactive Oxygen Species, Cell Respiration, Mitochondrial Proteins, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review